Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SYRE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSpyre Therapeutics reports Q1 2026 financial results
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release announcing first quarter 2026 financial results for period ended March 31, 2026. Actual financial figures are in the attached press release, not in the 8-K filing itself.
Item 2.02 verify on EDGAR → -
medium
This is a routine quarterly earnings announcement filing. Investors should review the full press release (Exhibit 99.1) for revenue, earnings, cash position, and any forward guidance.
8-K: Earnings view on EDGAR →
Summary
Spyre Therapeutics filed an 8-K on May 5, 2026 to announce its first quarter 2026 financial results. This is a standard quarterly earnings disclosure required by SEC rules. The filing itself contains no financial details—those are in the attached press release marked as Exhibit 99.1.
Retail investors should review the press release for key metrics including revenue, net income or loss, cash burn rate, and any updates to clinical trial timelines or business guidance. For a biotech company like Spyre, quarterly results typically focus on operating expenses, R&D spending, and runway (how long current cash will last). Watch for the company's next 10-Q filing, usually due within 45 days of quarter-end, which will provide full financial statements, management discussion, and risk factor updates that give more context than a press release alone.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Spyre Therapeutics announced Q1 2026 financial results via press release on May 5, 2026.
Added in current filing · verify on EDGAR →
On May 5, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures, only references the press release as Exhibit 99.1. This is a standard earnings announcement filing.
Event · Item 9.01 — Financial Statements and Exhibits
Spyre Therapeutics filed an 8-K attaching a press release regarding Q1 2026 financial results.
Added in current filing · verify on EDGAR →
Press release issued by Spyre Therapeutics, Inc. regarding its financial results for the first quarter ended March 31, 2026, dated May 5, 2026.
The company disclosed Q1 2026 financial results via press release attached as Exhibit 99.1. The 8-K itself contains no financial details; investors must review the press release for actual results, revenue, earnings, and guidance.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify